Earnings Call · Q1 FY2024·2024-04-25

Q1 24EPS -11.90%·Rev n/aQ4 23EPS +53.57%·Rev n/aQ3 23EPS +13.33%·Rev n/aQ2 23EPS +77.27%·Rev n/a⚠ consensus missing

Indivior Pharmaceuticals, Inc. INDV

Jason Thompson — Investor Relations or Communications

Mark Crossley — Chief Executive Officer

Ryan Preblick — Chief Financial Officer

−8.3%1d on move date−7.9% vs SPY3d−4.7%5d−6.3%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more INDV calls or request research access.

More INDV calls Browse calls Request research access